Oruka's experimental drug helps clear psoriasis in mid-stage study

Oruka Therapeutics said interim results showed its experimental psoriasis drug cleared the disease within 16 weeks, meeting the primary endpoint of a mid-stage trial. The positive readout sent shares up 43.4% in premarket trading, indicating a significant rerating of the company’s clinical pipeline.

Analysis

Oruka Therapeutics said interim results showed its experimental psoriasis drug cleared the disease within 16 weeks, meeting the primary endpoint of a mid-stage trial. The positive readout sent shares up 43.4% in premarket trading, indicating a significant rerating of the company’s clinical pipeline.